Advances in researches on hormonal refractory prostate cancer / 中华男科学杂志
National Journal of Andrology
; (12): 57-60, 2007.
Article
en Zh
| WPRIM
| ID: wpr-289045
Biblioteca responsable:
WPRO
ABSTRACT
In China, the incidence of prostate cancer has been increasing in recent years. Hormonal therapy has been the mainstay of the therapeutic options for metastatic diseases for many years. But many metastatic tumors progress at a median of two to five years and become hormonal refractory prostate cancer (HRPC). This article summarizes in the advances of diagnostic criteria, molecular biological features, prediction markers, new therapeutic agents and further researches to be undertaken concerning HRPC.
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Patología
/
Farmacología
/
Neoplasias de la Próstata
/
Biomarcadores de Tumor
/
Resistencia a Antineoplásicos
/
Diagnóstico
/
Quimioterapia
/
Antagonistas de Andrógenos
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Aged
/
Humans
/
Male
Idioma:
Zh
Revista:
National Journal of Andrology
Año:
2007
Tipo del documento:
Article